Navigation Links
Nile Therapeutics Reports 2008 First Quarter Financial Results
Date:5/15/2008

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced financial results for the first quarter ended March 31, 2008.

Net operating loss for the first quarter of 2008 was $3.1 million, or $0.13 per share, compared to $0.8 million, or $0.05 per share, for the first quarter of 2007. Weighted average shares outstanding for the first quarter for 2008 and 2007 were 24.1 million and 13.8 million, respectively.

Nile reported no revenue during the first quarter of 2008 and 2007. Research and development expenses were $2.0 million for the first quarter of 2008 compared to $0.6 million for the first quarter of 2007. General and administrative expenses were $1.2 million for the first quarter of 2008 compared to $0.2 million for the first quarter of 2007.

At March 31, 2008, Nile had cash and cash equivalents of $13.66 million compared to $16.23 million on December 31, 2007. This $2.57 million decrease occurred as cash was used for operations.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This pr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/22/2014)... , Sept. 22, 2014  WIRB-Copernicus Group ... ethical review services for clinical research, announced today ... (WIRB) has been reaccredited by the Association for ... which endeavors to improve safeguards for clinical research ... Donald A. Deieso , Ph.D., commented, "It is ...
(Date:9/21/2014)... University of Basel in Switzerland have succeeded in ... molecule for the first time. These extremely weak ... molecular properties and may also contribute to the ... results were published in the scientific journal ... the interaction between matter and light, is probably ...
(Date:9/20/2014)... 2014 MediVet America and ... groundbreaking surgery at the specialized Wolvega Horse Clinic. , ... flexor tendon was ruptured 90% and her deep digital ... a death sentence for a horse. , The clinic ... treatments . This revolutionary regenerative option for ruptured ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... and STATE COLLEGE, Pennsylvania, May 9, 2012 ... and SoftGenetics announced today that the two firms ... provide users of 454 Sequencing Systems the broad ... by SoftGenetics NextGENe® software. NextGENe® software ...
... 2012 Phalanx Biotech Group, a global genomic ... of manufacturing and testing for a proprietary targeted ... postnatal detection of microdeletions and microduplications related to ... intellectual delay disorders. Cyto OneArray ® ...
... Nev., May 8, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, is scheduled to ... http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Eleventh Annual JMP Securities Research ... Francisco, CA Goldman Sachs 33rd Annual Global ...
Cached Biology Technology:Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 2Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools 3Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray 2
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... (SACRAMENTO, Calif.) Mothers of children with autism are significantly ... during their pregnancies than the mothers of children who ... UC Davis MIND Institute has found. , Low iron ... autism in the child if the mother was 35 ... or if she suffered from metabolic conditions such as ...
(Date:9/21/2014)... of California, San Diego, have developed a program that ... activity of genes based on sequences of DNA. They ... to human embryonic cells in a paper published in ... of our cells have the same blueprint, the same ... lead author of the report. "Skin cells protect, nerve ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
... part of the skeletal support for the membrane in ... Joanny from the Physico Chemistry Curie Unit at the ... a well-defined layer beneath the cell outer membrane forms ... motor proteins within the cellular system. These findings, which ...
... NEW YORK , June 10, 2013   EyeLock Inc. ... the company has joined the Fast IDentity Online Alliance ... and more secure digital presence for consumers.  ... NXP, Nok Nok Labs and Validity, among others, ...
... that may be able to stop the spread of ... laboratory experiments conducted at Johannes Gutenberg University Mainz (JGU). ... order to evaluate their therapeutic potential. "The active substances ... killing off tumor cells that are resistant to more ...
Cached Biology News:Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 2Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords 3Substances from African medicinal plants could help stop tumor growth 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... Sf-900 II SFM.Sf21 Cells ... Spodoptera frugiperda (Fall Armyworm) ... The Sf21 cells are ... culture in Sf-900 II ...
Biology Products: